Abstract
Genetic and epigenetic defects of the p53 system have previously been associated with resistance to CDK4/6 inhibitors in women with HR+ breast cancer. Recent data from Kudo et al. demonstrate that CDK2-targeting agents may offer an effective strategy to circumvent such resistance by enforcing cellular senescence downstream of RBL2 dephosphorylation.
Author supplied keywords
Cite
CITATION STYLE
APA
Arrizabalaga, L., García-Torralba, E., Galluzzi, L., & Buqué, A. (2025, June 1). Targeting CDK2 to circumvent treatment resistance in HR+ breast cancer. Trends in Molecular Medicine. Elsevier Ltd. https://doi.org/10.1016/j.molmed.2024.12.009
Register to see more suggestions
Mendeley helps you to discover research relevant for your work.
Already have an account? Sign in
Sign up for free